Ser182

Site Information
PEDGVVIsEHGEDEM SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 34363530

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 )
Relevant cell line - cell type - tissue:	'3T3-L1, differentiated' (adipocyte) ( 2 ) , BaF3 ('B lymphocyte, precursor') [JAK3 (human), transfection] ( 1 )

Upstream Regulation
Treatments:	insulin ( 2 ) , MK-2206 ( 2 )

References
1	Degryse S, et al. (2017) Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia 32 28852199 Curated Info
2	Humphrey SJ, et al. (2013) Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2. Cell Metab 17, 1009-20 23684622 Curated Info